IFNA2 and tropical spastic paraparesis: Considering the similar clinical benefit reported for IFN-α and high-dose AA treatment, the latter, due to its milder in vivo side effects and lower cost, is an attractive therapeutic alternative in neglected diseases such as HAM/TSP.